Cyclophosphamide
Antineoplastic Combined Chemotherapy Protocols
Jilin UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Antineoplastic Combined Chemotherapy Protocols cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabilone NEMA Research, Inc. | Phase 4 | BB |
Docetaxel Jilin University | Phase 2 | CCC |
TAMOXIFEN Jilin University | Phase 2 | CCC |
Inno-206 Jilin University | Phase 2 | CCC |
Dexrazoxane Jilin University | Phase 2 | CCC |
VITAMIN B-1 Jilin University | Phase 2 | CCC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →